OPTION-EMEA Clinical Trial

A vizsgálat adatai

Ki végzi

Boston Scientific Corporation

Azonosító

NCT07349121

A regiszteradat frissítve

2026. október 27.

Eredeti leírás

The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case.A teljes eredeti leírásKevesebb

Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]

The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case.

The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.

Bevonási feltételek: Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN FLX™ Pro or WATCHMAN FLX™ for LAAC, per physician medical judgement and as per hospitals' standard of care; Subjects who are willing and able to provide informed consent; Subjects who are willing and able to participate in all testing associated with this clinical study at an approved investigational center; Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.

Kizáró feltételek: Subjects who underwent prior AF ablation procedure; Subjects with a myocardial infarction within 90 days prior to enrollment; Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within 90 days prior to enrollment; Any planned electrical cardioversion within 30 days following LAAC device implant; Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes; Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an atrial septal defect (ASD) / patent foramen ovale (PFO) device; Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present; Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina); Subjects with any contraindications to short term use of anticoagulation therapy for conditions different from atrial fibrillation; Already surgically closed or otherwise excluded LAA; The LAA anatomy does not accommodate a Closure Device; Known or suspected atrial myxoma; Presence of intracardiac thrombus*; Subjects with a presence of a mechanical valve prosthesis in any position; Subjects with a known inability to obtain vascular access; Subjects who are pregnant or planning to be pregnant; Subjects with a life expectancy of ≤ 1 year per investigator's opinion; Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.

ClinicalTrials.gov NCT07349121